Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 221

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

CSF amyloid- and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study

Alves, G., Bronnick, K., Aarsland, D., Blennow, K., Zetterberg, H., Ballard, C., Kurz, M. W., Andreasson, U., Tysnes, O.-B., Larsen, J. P., Mulugeta, E.·2010·Journal of Neurology, Neurosurgery & Psychiatry

Abstract

BACKGROUND: Alzheimer's disease (AD) pathology is found in a considerable portion of patients with Parkinson's disease (PD), particularly those with early dementia (PDD). Altered cerebrospinal fluid (CSF) levels of amyloid-β (Aβ) and tau proteins have been found in PDD, with intermediate changes for Aβ42 in non-demented PD. The authors investigated whether AD-related CSF protein levels are altered and relate to neuropsychological performance in early, untreated PD. METHODS: CSF concentrations of Aβ42, Aβ40 and Aβ38 were measured by electrochemiluminiscene and levels of total tau (T-tau) and phosphorylated tau (P-tau) by ELISA in 109 newly diagnosed, unmedicated, non-demented, community-based PD patients who had undergone comprehensive neuropsychological testing, and were compared with those of 36 age-matched normal controls and 20 subjects with mild AD. RESULTS: PD patients displayed significant reductions in Aβ42 (19%; p=0.009), Aβ40 (15.5%; p=0.008) and Aβ38 (23%; p=0.004) but not T-tau (p=0.816) or P-tau (p=0.531) compared with controls. CSF Aβ42 reductions in PD were less marked than in AD (53%; p=0.002). Sequential regression analyses demonstrated significant associations between CSF levels of Aβ42 (β=0.205; p=0.019), Aβ40 (β=0.378; p<0.001) and Aβ38 (β=0.288; p=0.001) and memory impairment, but not executive-attentional or visuospatial dysfunction. Tau protein levels did not correlate with cognitive measures. CONCLUSION: CSF Aβ levels are altered in a subset of patients with early PD and relate to memory impairment. Our study suggests that alterations in Aβ protein metabolism may contribute to the heterogeneity in pattern and course of cognitive decline associated with PD. Longitudinal studies are needed to clarify the clinical significance of CSF Aβ peptides as prognostic biomarkers in PD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jnnp.2009.199950

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 221

Metadata

Authors
Alves, G., Bronnick, K., Aarsland, D., Blennow, K., Zetterberg, H., Ballard, C., Kurz, M. W., Andreasson, U., Tysnes, O.-B., Larsen, J. P., & Mulugeta, E.
Venue
Journal of Neurology, Neurosurgery & Psychiatry
Publisher
BMJ
Published
2010-06-14
Volume
81
Issue
10
Pages
1080-1086
ISSN
0022-3050 (ISSN-L)
OpenAlex
W2019709557
Cited by
221
References
11
FWCI
12.16
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CSF amyloid- and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study. https://app.cochat.ai/papers/10.1136/jnnp.2009.199950
The paper
Alves, G., Bronnick, K., Aarsland, D., Blennow, K., Zetterberg, H., Ballard, C., Kurz, M. W., Andreasson, U., Tysnes, O.-B., Larsen, J. P., & Mulugeta, E. (2010). CSF amyloid- and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2009.199950

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.